Jun 7th, 2021

Biogen CEO Sees New Chapter in Fight Against Alzheimer's

Biogen CEO Michel Vounatsos discusses the implications of the FDA's approval of the company's controversial Alzheimer’s disease therapy, which will be sold under the name Aduhelm. He speaks on "Bloomberg Markets: The Close." (Source: Bloomberg)